Impartial Research Introduced at American Society of Hematology Annual Assembly Concludes Remestemcel-L Superior to Ruxolitinib in Medical Outcomes as Remedy for SR-aGvHD

Mesoblast Restricted (Nasdaq:MESO; ASX:MSB), world chief in allogeneic mobile medicines for inflammatory illnesses, as we speak introduced that an impartial peer-reviewed comparative evaluation of efficacy and security between remestemcel-L and ruxolitinib for therapy of steroid-refractory acute graft versus host illness (SR-aGvHD) was offered on the 67 th ASH Annual assembly in Florida this previous week. The impartial research authors concluded that remestemcel-L confirmed superior outcomes in full and total remission in contrast with ruxolitinib. 1

The meta-analysis concerned 2,732 sufferers (1,993 within the therapy arms and 523 within the management arms) throughout 11 research. Amongst therapy teams, 644 sufferers acquired remestemcel-L and 1,349 acquired ruxolitinib. Whereas each ruxolitinib and remestemcel-L considerably improved high quality of life in treating SR-aGvHD, remestemcel-L confirmed superior outcomes in full and total remission in addition to variations in hematology, cardiac and hepatic adversarial occasions. The authors additionally concluded that whereas each therapies exhibit favorable security profiles, scientific choices ought to think about the variations in adversarial occasions.

Ryoncil ^® is the primary mesenchymal stromal cell (MSC) product authorised by the U.S. Meals and Drug Administration (FDA) for any indication, and the one product authorised for kids below age 12 with SR-aGvHD. ²

The Highlight section of Blood , the flagship journal of ASH, featured FDA approval of Ryoncil ^® as an essential advance within the discipline for therapy of acute GvHD. ³

About Mesoblast
Mesoblast (the Firm) is a world chief in growing allogeneic (off-the-shelf) mobile medicines for the therapy of extreme and life-threatening inflammatory situations. The therapies from the Firm’s proprietary mesenchymal lineage cell remedy know-how platform reply to extreme irritation by releasing anti-inflammatory elements that counter and modulate a number of effector arms of the immune system, leading to vital discount of the damaging inflammatory course of.

Mesoblast’s Ryoncil ^® (remestemcel-L-rknd) for the therapy of steroid-refractory acute graft versus host illness (SR-aGvHD) in pediatric sufferers 2 months and older is the primary FDA-approved mesenchymal stromal cell (MSC) remedy. Please see the total Prescribing Info at www.ryoncil.com .

Mesoblast is dedicated to growing further cell therapies for distinct indications based mostly on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell know-how platforms. Ryoncil ^® is being developed for added inflammatory illnesses together with SR-aGvHD in adults and biologic-resistant inflammatory bowel illness. Rexlemestrocel-L is being developed for coronary heart failure and continual low again ache. The Firm has established business partnerships in Japan, Europe and China.

About Mesoblast mental property: Mesoblast has a powerful and in depth world mental property portfolio, with over 1,000 granted patents or patent purposes overlaying mesenchymal stromal cell compositions of matter, strategies of producing and indications. These granted patents and patent purposes present business safety extending by means of to no less than 2044 in all main markets.

About Mesoblast manufacturing: The Firm’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, mobile medicines. These cell therapies, with outlined pharmaceutical launch standards, are deliberate to be available to sufferers worldwide.

Mesoblast has areas in Australia, the USA and Singapore and is listed on the Australian Securities Alternate (MSB) and on the Nasdaq (MESO). For extra info, please see www.mesoblast.com , LinkedIn: Mesoblast Restricted and X: @Mesoblast

References / Footnotes

1. Ramteke HD, et al. Comparative efficacy and security of ruxolitinib and remestemcel-L within the therapy of steroid-refractory acute graft-versus-host illness: Systematic evaluate and meta-analysis. Poster. Blood 146 (2025) 6030. https://doi.org/10.1182/blood-2025-6030
2. Please see the total Prescribing Info at www.ryoncil.com
3. Etra A, Ferrara JLM, Levine JE. Remestemcel-L-rknd (Ryoncil): the primary authorised mobile remedy for steroid-refractory acute GVHD. Blood. 2025 October 16; 146(16): 1897–1901

Ahead-Wanting Statements
This press launch contains forward-looking statements that relate to future occasions or our future monetary efficiency and contain recognized and unknown dangers, uncertainties and different elements which will trigger our precise outcomes, ranges of exercise, efficiency or achievements to vary materially from any future outcomes, ranges of exercise, efficiency or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the secure harbor provisions of the Non-public Securities Litigation Reform Act of 1995 and different federal securities legal guidelines. Ahead-looking statements shouldn’t be learn as a assure of future efficiency or outcomes, and precise outcomes might differ from the outcomes anticipated in these forward-looking statements, and the variations could also be materials and adversarial. Ahead-looking statements embody, however usually are not restricted to, statements about: the initiation, timing, progress and outcomes of Mesoblast’s preclinical and scientific research, and Mesoblast’s analysis and improvement applications; Mesoblast’s capability to advance product candidates into, enroll and efficiently full, scientific research, together with multi-national scientific trials; Mesoblast’s capability to advance its manufacturing capabilities; the timing or chance of regulatory filings and approvals, manufacturing actions and product advertising and marketing actions, if any; the commercialization of Mesoblast’s RYONCIL for pediatric SR-aGVHD and every other product candidates, if authorised; regulatory or public perceptions and market acceptance surrounding using stem-cell based mostly therapies; the potential for Mesoblast’s product candidates, if any are authorised, to be withdrawn from the market attributable to affected person adversarial occasions or deaths; the potential advantages of strategic collaboration agreements and Mesoblast’s capability to enter into and preserve established strategic collaborations; Mesoblast’s capability to ascertain and preserve mental property on its product candidates and Mesoblast’s capability to efficiently defend these in circumstances of alleged infringement; the scope of safety Mesoblast is ready to set up and preserve for mental property rights overlaying its product candidates and know-how; estimates of Mesoblast’s bills, future revenues, capital necessities and its wants for added financing; Mesoblast’s monetary efficiency; developments referring to Mesoblast’s opponents and trade; and the pricing and reimbursement of Mesoblast’s product candidates, if authorised. It is best to learn this press launch along with our threat elements, in our most not too long ago filed stories with the SEC or on our web site. Uncertainties and dangers which will trigger Mesoblast’s precise outcomes, efficiency or achievements to be materially totally different from these which can be expressed or implied by such statements, and accordingly, you shouldn’t place undue reliance on these forward-looking statements. We don’t undertake any obligations to publicly replace or revise any forward-looking statements, whether or not because of new info, future developments or in any other case.

Launch licensed by the Chief Government.

For extra info, please contact: